Secukinumab in plaque psoriasis—results of two phase 3 trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). RESULTS: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. CONCLUSIONS: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An Ab targeting IL-17 (secukinumab) was approved in 2016 to treat moderate-severe plaque psoriasis [54].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Cited by
Items 201–300 of 1,001
Bilal, J., Berlinberg, A. J., Bhattacharjee, S., Trost, J. R., Riaz, I. B., & Kurtzman, D. J. B. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1422591 · Cited by 137
Malik, K., He, H., Huynh, T. N., Tran, G., Mueller, K. A., Doytcheva, K., Renert‐Yuval, Y., Czarnowicki, T., Magidi, S., Chou, M. M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.03.021 · Cited by 140
“IL-17 blockade with therapeutic antibodies resolves most of the clinical or molecular psoriasis phenotype.(55,120,130,131) In contrast, the ichthyoses are caused by genetic defects primarily in keratinocyte structural genes or enzymes, leading to barrier abnormalities that are most often present at birth.”
Safety of secukinumab in the treatment of psoriasis
Blauvelt, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221923 · Cited by 135
Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis
Lockshin, B., Balagula, Y., & Merola, J. F. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.02.040 · Cited by 132
Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis
McGinley, A. M., Edwards, S. C., Raverdeau, M., & Mills, K. H. G. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.01.001 · Cited by 147
IκBζ is a key driver in the development of psoriasis
Johansen, C., Mose, M., Ommen, P., Bertelsen, T., Vinter, H., Hailfinger, S., Lorscheid, S., Schulze-Osthoff, K., & Iversen, L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509971112 · Cited by 125
New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines
Renert-Yuval, Y., & Guttman-Yassky, E. (2020) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.10.005 · Cited by 125
Cytokine‐regulated Th17 plasticity in human health and diseases
Cerboni, S., Gehrmann, U., Preite, S., & Mitra, S. (2020) · Immunology · doi:10.1111/imm.13280 · Cited by 139
Cytokines and intestinal epithelial permeability: A systematic review
Meyer, F., Wendling, D., Demougeot, C., Prati, C., & Verhoeven, F. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103331 · Cited by 153
Berry, S. P. D.-G., Dossou, C., Kashif, A., Sharifinejad, N., Azizi, G., Hamedifar, H., Sabzvari, A., & Zian, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108402 · Cited by 124
Raychaudhuri, S. P., Wilken, R., Sukhov, A., Raychaudhuri, S. K., & Maverakis, E. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.10.009 · Cited by 141
Davidson, L., van den Reek, J. M. P. A., Bruno, M., van Hunsel, F. P. A. M., Herings, R. M. C., Matzaraki, V., Boahen, C. K., Kumar, V., Groenewoud, H., van de Veerdonk, F. L., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100266 · Cited by 146
The Role of IL-17 in Protection against Mucosal Candida Infections
Mengesha, B., & Conti, H. R. (2017) · Journal of Fungi · doi:10.3390/jof3040052 · Cited by 136
“Secukinumab (AIN457) and Ixekizumab (LY2439821), both humanized anti-IL-17A monoclonal antibodies have recently been approved by the United States Food and Drug Administration (FDA) for moderate-to-severe plaque psoriasis, psoriatic arthritis, as well as ankylosing spondylitis [90,91].”
BackgroundMenter, A., Krueger, G. G., Paek, S. Y., Kivelevitch, D. N., Adamopoulos, I. E., & Langley, R. G. B. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00483-2 · Cited by 142
“Secukinumab is a fully human IgG1j monoclonal antibody (mAb) [51], and ixekizumab is a humanized IgG4 mAb [52, 53]; these agents selectively bind and neutralize IL17A.”
BackgroundSelf-citationMoy, A. P., Murali, M. R., Kroshinsky, D., Duncan, L. M., & Nazarian, R. M. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2 · Cited by 123
Interleukin 23–Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris
Feldmeyer, L., Mylonas, A., Demaria, O., Mennella, A., Yawalkar, N., Laffitte, E., Hohl, D., Gilliet, M. F., & Conrad, C. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.5384 · Cited by 132
IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid
Chakievska, L., Holtsche, M. M., Künstner, A., Goletz, S., Petersen, B., Thaçi, D., Ibrahim, S. M., Ludwig, R. J., Franke, A., Sadik, C. D., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.09.003 · Cited by 133
Clinical meaningfulness of complete skin clearance in psoriasis
Strober, B. E., Papp, K. A., Lebwohl, M., Reich, K., Paul, C. F., Blauvelt, A., Gordon, K. B., Milmont, C. E., Viswanathan, H. N., Li, J., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.03.026 · Cited by 128
Bagel, J., Duffin, K. C., Moore, A. Y., Ferris, L. K., Siu, K., Steadman, J., Kianifard, F., Nyirady, J., & Lebwohl, M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.05.033 · Cited by 129
Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis
Jeon, C., Sekhon, S., Yan, D., Afifi, L., Nakamura, M., & Bhutani, T. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1356498 · Cited by 128
“001).(40) In addition to a placebo group, FIXTURE used an active-control arm, comparing secukinumab to etanercept.”
BackgroundMethodInfluentialInterleukin‐17‐producing γδ T ( γδ 17) cells in inflammatory diseases
Akitsu, A., & Iwakura, Y. (2018) · Immunology · doi:10.1111/imm.12993 · Cited by 128
Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus
Solimani, F., Pollmann, R., Schmidt, T., Schmidt, A., Zheng, X., Savai, R., Mühlenbein, S., Pickert, J., Eubel, V., Möbs, C., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01808 · Cited by 130
“Secukinumab, ustekinumab, and guselkumab were chosen for compassionate use in the studied patients with extensive or recalcitrant LP because they are licensed for the treatment of the Th17-associated inflammatory disorders, psoriasis vulgaris, psoriatic arthritis and Crohn’s disease (16, 17).”
BackgroundMicronutrients in autoimmune diseases: possible therapeutic benefits of zinc and vitamin D
Weßels, I., & Rink, L. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108240 · Cited by 132
Sepriano, A. R., Regel, A., van der Heijde, D. M. F. M., Braun, J., Baraliakos, X., Landewé, R., den Bosch, F. E. V., Falzon, L., & Ramiro, S. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000396 · Cited by 120
“Of note, for psoriasis, in the light of the results of two head-to-head trials (secukinumab 300 mg compared to etanercept and to ustekinumab), secukinumab is approved as a first-line systemic treatment for adults with moderate-to-severe plaque psoriasis.(68) 69 Safety data on secukinumab are still limited, but the ove…”
BackgroundSecukinumab: First Global Approval
Sanford, M., & McKeage, K. (2015) · Drugs · doi:10.1007/s40265-015-0359-0 · Cited by 118
“In the ERASURE trial, adverse events during weeks 1–12 occurred in 60, 55 and 47 % of patients in the secukinumab 150, 300 mg and placebo groups, respectively; in the corresponding groups, 27, 29 and 16 % of patients had infections and infestations [11].”
BackgroundMethodInfluentialParamsothy, S., Rosenstein, A. K., Mehandru, S., & Colombel, J. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0050-3 · Cited by 133
Meng, J., Li, Y., Fischer, M. J. M., Steinhoff, M. S., Chen, W., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696784 · Cited by 124
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature
Gossec, L., McGonagle, D., Korotaeva, T. V., Lubrano, E., de Miguel, E., Østergaard, M., & Behrens, F. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.170449 · Cited by 114
Ohtsuki, M., Kubo, H., Morishima, H., Goto, R., Zheng, R., & Nakagawa, H. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14504 · Cited by 114
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111
Weinstein, J. E., & Pepple, K. L. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000466 · Cited by 117
“Secukimumab (Consentyx, Novartis, Basel, Switzerland) is a Food and Drug Administration (FDA)-approved human antibody directed against IL-17A for the treatment of psoriasis [21,22], psoriatic arthritis [23,24] and ankylosing spondylitis [25].”
Fungal Infections and New Biologic Therapies
Vallabhaneni, S., & Chiller, T. M. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0572-1 · Cited by 117
The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
Renert‐Yuval, Y., & Guttman‐Yassky, E. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0542-7 · Cited by 120
“Secukinumab is a recombinant, high-affinity, fully human IgG1j that selectively inhibits IL-17A, FDA-approved for the treatment of psoriasis [101, 102, 106].”
BackgroundKrueger, J. G., & Brunner, P. M. (2018) · Experimental Dermatology · doi:10.1111/exd.13467 · Cited by 111
Pathogenesis, multi-omics research, and clinical treatment of psoriasis
Yu, J., Zhao, Q., Wang, X., Zhou, H., Hu, J. Y., Gu, L., Hu, Y., Zeng, F., Zhao, F., Yue, C., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102916 · Cited by 124
Inflammation, Immunity, and Oxidative Stress in Hypertension—Partners in Crime?
Barrows, I. R., Ramezani, A., & Raj, D. S. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.03.001 · Cited by 127
“[88] Monoclonal antibodies against IL-17A or IL-17RA, the IL-17A receptor have shown promising results in in patients with psoriasis.[46;59] However, a meta-analysis examining the effect of anti-TNFα agents in patients with rheumatoid arthritis is associated with increased risk of developing hypertension.”
ResultInterleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases
Wasilewska, A., Winiarska, M., Olszewska, M., & Rudnicka, L. (2016) · Advances in Dermatology and Allergology · doi:10.5114/ada.2016.61599 · Cited by 110
“The most common side effects were nasopharyngitis, headache and diarrhea [19].”
BackgroundShifting the focus – the primary role of IL ‐23 in psoriasis and other inflammatory disorders
Gooderham, M., Papp, K. A., & Lynde, C. W. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14868 · Cited by 127
Forman, S. B., Pariser, D. M., Poulin, Y. P., Vincent, M. S., Gilbert, S. A., Kieras, E., Qiu, R., Yu, D., Papacharalambous, J., Tehlirian, C., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.962 · Cited by 109
Vieyra-Garcia, P. A., & Wolf, P. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107784 · Cited by 125
Association between Biologic Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis
Singla, S., Putman, M., Liew, J. W., & Gordon, K. B. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00034-6 · Cited by 115
Pathogenic stromal cells as therapeutic targets in joint inflammation
Dakin, S. G., Coles, M. C., Sherlock, J. P., Powrie, F. M., Carr, A. J., & Buckley, C. D. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0112-7 · Cited by 109
Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer
Brevi, A., Cogrossi, L. L., Grazia, G., Masciovecchio, D., Impellizzieri, D., Lacanfora, L., Grioni, M., & Bellone, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.565470 · Cited by 121
“Finally, signaling integrations between IL-17 and components of C-type lectin receptors have been reported in keratinocytes during psoriasis (90).”
BackgroundIL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells
Chen, X., Cai, G., Liu, C., Zhao, J., Gu, C., Wu, L., Hamilton, T. A., Zhang, C.-J., Ko, J., Zhu, L., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20171849 · Cited by 106
“, 2013), anti–IL-17A antibody (Cosentyx; Novartis) is highly efficacious in treating psoriasis (Langley et al., 2014; Blauvelt et al., 2017), an inflammatory skin disease due to excessive hyperproliferation of keratinocytes (Bata-Csörgö and Szell, 2012).”
BackgroundCytokine-Modulating Strategies and Newer Cytokine Targets for Arthritis Therapy
Venkatesha, S. H., Dudics, S., Acharya, B., & Moudgil, K. D. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010887 · Cited by 116
“Among these, IL-17A has dominant role in the pathogenesis of RA.”
BackgroundInfluentialThe Role of IL-17 Cytokines in Psoriasis
Mosca, M., Hong, J., Hadeler, E., Hakimi, M., Liao, W. J., & Bhutani, T. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s240891 · Cited by 127
“Secukinumab has been evaluated in two, double-blind, placebo-controlled phase III clinical trials, ERASURE and FIXTURE.(58) In the ERASURE study, secukinumab 300 mg and 150 mg were compared to placebo, and in the FIXTURE study, etanercept was used as an active comparator.”
BackgroundMethodResultInfluentialDeng, Z., Wang, S., Wu, C., & Wang, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1124628 · Cited by 123
“The anti-IL-17 agents secukinumab (SEC), ixekizumab (IXE), and brodalumab (BRO), which were launched in January 2015, April 2016, and July 2017, respectively, are monoclonal IgG4 antibodies directed against IL-17A (SEC and IXE), or against the IL-17 receptor (BRO) (Langley et al., 2014; Griffiths et al., 2015; Lebwohl…”
BackgroundBodemer, C., Kaszuba, A., Kingo, K., Tsianakas, A., Morita, A., Rivas, E., Papanastasiou, P., Keefe, D. L., Patekar, M., Charef, P., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17002 · Cited by 106
New evidence on the management of spondyloarthritis
Sieper, J., & Poddubnyy, D. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.42 · Cited by 110
Paul, C. F., Griffiths, C. E. M., van de Kerkhof, P. C. M., Puig, L., Dutronc, Y., Henneges, C., Dossenbach, M. R. K., Hollister, K., & Reich, K. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.039 · Cited by 108
“The types 261 of common adverse events and discontinuation rates in IXORA-S for the ustekinumab and 262 ixekizumab treatment groups were comparable and in line with those reported in previous trials 263 of these treatments,(7,8,12,13,23) and those of other biologic agents.(10,11,24,25) 264”
ResultSecukinumab Therapy for Netherton Syndrome
Luchsinger, I., Knöpfel, N., Theiler, M., Claustres, M. B. D., Barbieux, C., Schwieger‐Briel, A., Brunner, C., Donghi, D., Buettcher, M., Meier-Schiesser, B., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.1019 · Cited by 103
Reich, K., Sullivan, J. R., Arenberger, P., Mrowietz, U., Jazayeri, S., Augustin, M., Parneix, A., Regnault, P., You, R., & Milutinovic, M. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17351 · Cited by 108
Sawyer, L., Cornic, L., Levin, L. Å., Gibbons, C. M., Møller, A. H., & Jemec, G. B. E. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15277 · Cited by 108
Biologics for the primary care physician: Review and treatment of psoriasis
Schadler, E. D., Ortel, B. J., & Mehlis, S. L. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2018.06.001 · Cited by 114
Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?
Siebert, S., Millar, N. L., & McInnes, I. B. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213654 · Cited by 106
Role of Innate Immune Cells in Psoriasis
Sato, Y., Ogawa, E., & Okuyama, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186604 · Cited by 113
Gottlieb, A. B., Deodhar, A. A., McInnes, I. B., Baraliakos, X., Reich, K., Schreiber, S., Bao, W., Marfo, K., Richards, H. B., Pricop, L., et al. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.563 · Cited by 107
“Two PsO clinical trials (19) included patients with a prior history of biologics other than TNFi (alefacept, briakinumab, efalizumab and ustekinumab) after an appropriate washout period.”
BackgroundBalak, D., van Doorn, M. B. A., Arbeit, R. D., Rijneveld, R., Klaassen, E. S., Sullivan, T., Brevard, J. A., Thio, H. B., Prens, E. P., Burggraaf, J., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.09.015 · Cited by 100
Pirrò, F., Caldarola, G., Chiricozzi, A., Burlando, M., Mariani, M., Parodi, A., Peris, K., & SIMONE, C. D. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01080-z · Cited by 108
Marzo‐Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Martin, R., Readie, A., Richards, H., Porter, B. O., & on behalf of the Measure 2 Study Group (2017) · Arthritis Care & Research · doi:10.1002/acr.23233 · Cited by 105
“the treatment of psoriasis (16), psoriatic arthritis (17–19), and AS (15) and is approved for the treatment of these conditions in Europe, the US, and numerous other coun-”
BackgroundResultMease, P. J., Genovese, M. C., Weinblatt, M. E., Peloso, P. M. J., Chen, K., Othman, M. I. A., Li, Y., Mansikka, H. T., Khatri, A., Wishart, N., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40579 · Cited by 104
“with psoriasis (46,47) and on PsA skin and joint disease end points (12,13), as compared to its impact on joint”
BackgroundIL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients
Shi, Y., Chen, Z., Zhao, Z., Yu, Y., Fan, H., Xu, X., Bu, X., & Gu, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01865 · Cited by 106
New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis
Karczewski, J., Dobrowolska, A., Rychlewska-Hańczewska, A., & Adamski, Z. (2016) · Autoimmunity · doi:10.3109/08916934.2016.1166214 · Cited by 103
“That IL-17A plays a key role in PsO and PsA is further supported by evidence that clinical response to various therapies depend on IL-17A downregulation in lesional skin [67,68], as well as by the therapeutic results of phase III clinical trials with IL-17A inhibitors in both diseases [69,70].”
BackgroundInteractions between neutrophils and T-helper 17 cells
Fan, X., Shu, P., Wang, Y., Ji, N., & Zhang, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1279837 · Cited by 116
Li, X., Andersen, K. M., Chang, H., Curtis, J. R., & Alexander, G. C. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216102 · Cited by 103
Strand, V., Mease, P. J., Gossec, L., Elkayam, O., den Bosch, F. E. V., Zuazo, J., Pricop, L., & Mpofu, S. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209055 · Cited by 98
The many faces of interleukin-17 in inflammatory skin diseases
Speeckaert, R., Lambert, J., Grine, L., Gele, M. V., Schepper, S. D., & van Geel, N. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14703 · Cited by 103
Susceptibility to chronic inflammation: an update
Nasef, N. A., Mehta, S. Y., & Ferguson, L. R. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1914-5 · Cited by 114
Genome‐wide association studies in Crohn's disease: Past, present and future
Verstockt, B., Smith, K. G. C., & Lee, J. C. (2018) · Clinical & Translational Immunology · doi:10.1002/cti2.1001 · Cited by 111
“Of the few studies that have been performed in individuals of non-Caucasian descent, the results suggest that there may be some important population-based differences in the genetic risk of CD.”
BackgroundInfluentialItch: an under‐recognized problem in psoriasis
Elewski, B. E., Alexis, A. F., Lebwohl, M., Gold, L. S., Pariser, D. M., Rosso, J. Q. D., & Yosipovitch, G. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15450 · Cited by 104
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases
Kingsmore, K. M., Grammer, A. C., & Lipsky, P. E. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0337-0 · Cited by 100
Interventions for chronic palmoplantar pustulosis
Obeid, G., Do, G., Kirby, L. C., Hughes, C., Sbidian, É., & Cleach, L. L. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011628.pub2 · Cited by 98
Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics
Banchereau, R., Cepika, A., Banchereau, J., & Pascual, V. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052225 · Cited by 121
Miossec, P. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000284 · Cited by 96
“the Food and Drug Administration (FDA) in early 2015, based on very impressive results on skin lesions.(35) These effects are described by the dermatologists as never seen”
BackgroundArakawa, A., Vollmer, S., Besgen, P., Galinski, A., Summer, B., Kawakami, Y., Wollenberg, A., Dornmair, K., Spannagl, M., Ruzicka, T., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.12.024 · Cited by 103
Robbins, K., Bissonnette, R., Maeda-Chubachi, T., Ye, L., Peppers, J., Gallagher, K., & Kraus, J. E. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.10.037 · Cited by 93
Anti-IL17 therapies for psoriasis
Silfvast‐Kaiser, A., Paek, S. Y., & Menter, A. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1555235 · Cited by 96
“Both drugs had low rates of neutropenia (≤1%) [15].”
BackgroundReich, K., Griffiths, C. E. M., Gordon, K. B., Papp, K. A., Song, M., Randazzo, B., Li, S., Shen, Y.-K., Han, C., Kimball, A. B., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.11.040 · Cited by 93
Ohtsuki, M., Morita, A., Abe, M., Takahashi, H., Seko, N., Karpov, A., Shima, T., Papavassilis, C., Nakagawa, H., & subgroup, T. E. S. J. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12668 · Cited by 101
IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology
Nies, J. F., & Panzer, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00341 · Cited by 104
Lin, X., Gaudino, S. J., Jang, K. K., Bahadur, T., Singh, A. A., Banerjee, A., Beaupre, M., Chu, T. H., Wong, H. T., Kim, C.-K., et al. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.016 · Cited by 107
“Monoclonal antibodies against IL-17A or IL17RA have been shown to be highly effective treatments for moderate to severe plaque psoriasis (Gordon et al., 2016; Langley et al., 2014; Papp et al., 2012).”
BackgroundTargeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Zwicky, P., Unger, S., & Becher, B. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191123 · Cited by 91
Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis
Senra, L., Stalder, R., Martínez, D. Á., Chizzolini, C., Boehncke, W., & Brembilla, N. C. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.06.009 · Cited by 103
“Blockade of IL-17RA ameliorates psoriasis clinical signs and symptoms at least as effectively as neutralization of IL17A (Langley et al., 2014; Papp et al., 2016), suggesting that other IL-17 family members may play a clinical relevant role.”
BackgroundVaher, H., Runnel, T., Aab, A., Baurecht, H., Rodríguez, E., Magilnick, N., Urgard, E., Šahmatova, L., Prans, E., Maslovskaja, J., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.012 · Cited by 108
“Recent clinical studies, in which patients with psoriasis were successfully treated with different IL-17 antagonists, point out the pivotal role of IL-17 in the pathogenesis of psoriasis (Griffiths et al., 2015; Langley et al., 2014; Papp et al., 2012a, 2012b).”
BackgroundDrug survival of biologic treatments in psoriasis: a systematic review
No, D. J., Inkeles, M. S., Amin, M., & Wu, J. J. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1398393 · Cited by 91
Loft, N., Vaengebjerg, S., Halling, A., Skov, L., & Egeberg, A. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16073 · Cited by 104
Menegatti, S., Bianchi, E., & Rogge, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00382 · Cited by 100
Langan, E. A., Künstner, A., Miodovnik, M., Zillikens, D., Thaçi, D., Baines, J. F., Ibrahim, S. M., Solbach, W., & Knobloch, J. K. ‐. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17989 · Cited by 100
Slowikowski, K., Nguyen, H. N., Noss, E. H., Simmons, D. P., Mizoguchi, F., Watts, G. F. M., Gurish, M. F., Brenner, M. B., & Raychaudhuri, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912702117 · Cited by 89
Boehner, A., Navarini, A. A., & Eyerich, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13699 · Cited by 89
Ly, K., Smith, M. P., Thibodeaux, Q. G., Reddy, V. D., Liao, W. J., & Bhutani, T. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1679625 · Cited by 100
“Furthermore, IL-17 inhibitors have demonstrated efficacy over TNF-α in a head-to-head clinical trial of secukinumab compared to etanercept [26] and ixekizumab compared to etanercept [42].”
BackgroundLu, H., Hong, T., Jiang, Y., Whiteway, M., & Zhang, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114960 · Cited by 89
Sexy again: the renaissance of neutrophils in psoriasis
Schön, M. P., Broekaert, S. M. C., & Erpenbeck, L. (2017) · Experimental Dermatology · doi:10.1111/exd.13067 · Cited by 100
Forcade, É., Paz, K. G., Flynn, R. P., Griesenauer, B., Amet, T., Li, W., Liu, L., Bakoyannis, G., Jiang, D., Chu, H. W., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92111 · Cited by 93
Pathogenic role of tissue-resident memory T cells in autoimmune diseases
Wu, H., Liao, W., Li, Q., Long, H., Yin, H., Zhao, M., Chan, V. S. F., Lau, C.-S., & Lu, Q. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.03.014 · Cited by 105
Prinz, I., Sandrock, I., & Mrowietz, U. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20191397 · Cited by 91
“Subsequently, a large clinical trial program was started, leading to the registration of secukinumab for plaque psoriasis in 2015 with a dose of 300 mg subcutaneously given every 4 wk in maintenance therapy after an updosing in weekly intervals in the initial 4 wk of therapy (Langley et al., 2014).”
BackgroundPhillippo, D., Dias, S., Ades, A. E., & Welton, N. J. (2020) · Statistics in Medicine · doi:10.1002/sim.8759 · Cited by 97
Strober, B. E., Bissonnette, R., Fiorentino, D. F., Kimball, A. B., Naldi, L., Shear, N. H., Goyal, K., Fakharzadeh, S. S., Calabro, S., Langholff, W. K., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.12.017 · Cited by 100
Kavanaugh, A., Mease, P. J., Reimold, A. M., Tahir, H., Rech, J., Hall, S., Geusens, P., Wang, Z., Pricop, L., Mpofu, S., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.23111 · Cited by 87
“In addition to broad and sustained efficacy, the high retention rate in FUTURE-1 also reflects the acceptable tolerability and safety profile of secukinumab, which was consistent with that previously reported (6,10,11,13).”
ResultThe critical role of macrophages in the pathogenesis of hidradenitis suppurativa
Shah, A., Alhusayen, R. O., & Amini‐Nik, S. (2017) · Inflammation Research · doi:10.1007/s00011-017-1074-y · Cited by 98
“[157], brodalumab [158], and ixekizumab [159] have shown promise in the management of moderate-to-severe psoriasis in phase III clinical trials.”
Background
Metadata
- Authors
- Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C.
- Affiliations
- Dalhousie University (CA)
- University of Alabama at Birmingham (US)
- Mount Sinai Hospital (US)
- Dermatologikum Hamburg (DE)
- Manchester Academic Health Science Centre (GB)
- Probity Medical Research (CA)
- Hospital de Sant Pau (ES)
- Jikei University School of Medicine (JP)
- University of Iceland (IS)
- National Taiwan University (TW)
- Center for Clinical Studies (US)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 326-338
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973354423
- Cited by
- 1,997
- References
- 25
- Citations by year
- 2026: 96 · 2025: 107 · 2024: 116 · 2023: 142 · 2022: 146 · 2021: 165 · 2020: 198 · 2019: 230 · 2018: 201 · 2017: 223 · 2016: 203 · 2015: 146 · 2014: 19
- FWCI
- 90.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- secukinumab, plaque psoriasis, IL-17A, anti-IL-17A monoclonal antibody, etanercept, PASI 75, dosing regimen, biologic therapy, treatment efficacy and safety, erasure, fixtures, Psoriasis Area and Severity Index
- MeSH terms
- Etanercept, Adult, Antibodies, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents, Infections, Injections, Subcutaneous, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.